Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. director Shalini Sharp filed an amended Form 3 to correct her initial insider holdings. The amendment now reflects ownership of 9 American Depositary Shares, held directly. A footnote explains that each ADS represents 13 Ordinary Shares. This update does not report any new buy or sell transactions; it simply adds ADS that were omitted from the original Form 3 and subsequent Forms 4, leaving all other previously reported information unchanged.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised employee share options covering 4,316 Ordinary Shares at exercise prices of $12.23, $16.41, and $14.96 per share. The options were represented as Share Options (Right to Buy) and convert into Ordinary Shares.
On the same date, he sold 332 American Depositary Shares at an average price of $310.72 per ADS in an open-market transaction made under a Rule 10b5-1 trading plan. Following these transactions, he directly owns 318,370 Ordinary Shares and no American Depositary Shares.
BeOne Medicines Ltd. reports that the U.S. FDA has granted accelerated approval for BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor, to treat adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies, including a BTK inhibitor.
The decision is based on a Phase 1/2 study showing a 52% overall response rate, a 16% complete response rate, and a median duration of response of 15.8 months. Approval is conditional on confirmatory trial results, and the label carries important safety warnings, including tumor lysis syndrome and serious infections.
ONC submitted a Form 144 reporting the proposed sale of 1,328 ADS on 05/13/2026 following an exercise of stock options. The filing also discloses prior Rule 10b5-1 sales of 332 ADS on 04/08/2026 for $103,447.88 and 341 ADS on 03/11/2026 for $102,300.00.
BeOne Medicines Ltd. filed a post-effective Form S-3 shelf registration to replace an expiring registration, registering up to 398,880,905 Ordinary Shares, including 374,373,961 Ordinary Shares represented by 28,797,997 ADSs (each ADS = 13 Ordinary Shares). The prospectus states BeOne is not selling any shares here and will not receive proceeds; proceeds, if any, will go to the listed selling shareholders. The registration covers resale by Amgen, entities affiliated with Baker Bros. Advisors and HHLR Advisors under existing registration rights. The filing notes cross‑listings on HKEx, Nasdaq and the STAR Market and highlights business, liquidity and China‑related operational risk disclosures incorporated by reference.
BeOne Medicines Ltd. files a new shelf registration on Form S-3 to replace an expiring registration and permit, from time to time, primary offerings and resales of ordinary shares, ADSs, preferred shares, debt securities, warrants and units.
The shelf contemplates offerings by the company and selling shareholders, with proceeds to the company disclosed only in future prospectus supplements; the company discloses key context figures including $731 million in cash and cash equivalents as of March 31, 2026, approximately 1,540,975,898 Registered Shares issued, and recent product and pipeline highlights (BRUKINSA sales of $3.9 billion in 2025). The registration replaces an earlier S-3 that would expire on May 9, 2026.
BeOne Medicines Ltd. reported Q1 2026 revenue of $1.51B, up 35.5% from a year earlier, driven mainly by strong growth in BRUKINSA and TEVIMBRA. Net income rose sharply to $227.4M, compared with near breakeven a year ago, as higher sales and improved gross margin outpaced increased R&D and commercial spending.
Product revenue reached $1.49B, led by BRUKINSA at $1.09B (up 38.3%) and steady growth in Amgen-partnered products. Gross margin improved to 88.8% on a richer mix of BRUKINSA and efficiency gains. Operating cash flow climbed to $201.3M, lifting cash, cash equivalents and restricted cash to $4.85B, while total debt stood at $1.08B and the IMDELLTRA royalty financing liability at $904.4M.
BeOne Medicines reported a very strong first quarter of 2026, with total revenue of $1.51 billion, up 35% from the prior year. Net product revenue was $1.49 billion, driven mainly by oncology medicines.
Flagship BTK inhibitor BRUKINSA generated global sales of $1.1 billion, up 38%, including U.S. sales of $761 million (up 35%). TEVIMBRA reached $206 million in global sales, while Amgen in-licensed products contributed $142 million.
GAAP income from operations rose to $249.9 million and GAAP net income to $227.4 million, compared with nearly break-even a year earlier. GAAP diluted earnings were $1.96 per ADS, and non‑GAAP diluted earnings were $3.24 per ADS. Free cash flow improved to $160.5 million from negative levels.
The company raised full‑year 2026 guidance, now expecting total revenue of $6.3 billion–$6.5 billion and GAAP operating income of $750 million–$850 million. Management highlighted a broad oncology pipeline with multiple late‑stage milestones and regulatory decisions anticipated through 2026–2027.